Login

Gujarat Themis Biosyn Ltd.

₹361.3

Overview Charts Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Corp. Action Documents
Consolidated
Standalone

Gujarat Themis Biosyn Ltd.

  • NSE : GUJTHEM
Add Alert
Add Watchlist

₹361.3

₹361.3

6.8 (1.92%) - 18 Aug 2025 04:31 PM
  • NSE : GUJTHEM

About Company

Incorporated in 1981 as a joint sector company with GIIC Ltd. and Chemosyn (P) Ltd. Commenced production in August, 1985 by producing Erythromycin and Erythromycin salts and formulations. The Company was taken over during June 1991 by Pharmaceutical Business Group (India) Ltd. (PBG); a unique consortium of five competing drug Companies - Themis Medicare Ltd., Kopran Ltd., Anant & Co., Cadila Health Care Ltd. (Zydus) and Lyka Labs Ltd.. The Company entered into Technical & Financial collaboration with Yuhan Corporation, South Korea. With Yuhan's know-how, GTBL became India's first Company to start commercial production of Anti-tuberculosis drug Rifampicin. The company is principally engaged in the activities pertaining to manufacturing of pharmaceuticals and medicinal chemicals.

Market Cap. ₹ 3,937 Cr.
52 Week - High/Low ₹ 405/208
P/E Ratio 89.30
P/B Ratio 19.76
Enterprise Value -
ROE % 33.76
RSI Value 50.72
EMA 50 349.19
EMA 200 349.88
Market Cap. ₹ 3,937 Cr.
52 Week - High/Low ₹ 405/208
P/E Ratio N/A
P/B Ratio N/A
Enterprise Value -
ROE % N/A
RSI Value 50.72
EMA 50 349.19
EMA 200 349.88
Add Parameters

Growth

Chart Icon
View Full Chart

Valuation

Calculators

Peer Comparison

Industry - Pharmaceuticals & Drugs

* Please refer to the Standalone data if Consolidated financial data for the company is not available.

Shareholding Pattern Numbers in percentages

Insight market
Terms | Privacy | Contact Us
Copyright © 2025 All rights reserved with INVESMATE INSIGHTS PRIVATE LIMITED | All logos and Trademarks registered with their respective owners.